Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Antibodies, Neoplasm (0):
Recent article
Antibodies, Neoplasm
Abstract
| < More recent | Older article > |
Bulletin du cancer (98)8 2011
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice of hematologic malignancies. Acute graft versus host disease (GvHD) is common after HSCT and directly related to graft versus leukemia effect. Little progress has been done in the treatment of acute...
|
PMID: 21835730
PDF is available here.
PDF is available here.
Abstract
We have analyzed ESCC tissues and adjacent normal tissues by two-dimensional electrophoresis (2DE) and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) analysis. The results showed that a total of 104 protein spots with different expression levels were foun...
|
PMID: 21517111
PDF is available here.
PDF is available here.
New England Journal of Medicine (364)20 2011
Abstract
We randomly assigned patients to receive alemtuzumab or conventional induction therapy (basiliximab or rabbit antithymocyte globulin). Patients were stratified according to acute rejection risk, with a high risk defined by a repeat transplant, a peak or current value of panel-reactive antibodies of...
|
PMID: 21591943
PDF is available here.
PDF is available here.
New England Journal of Medicine (364)20 2011
Abstract
Abstract
Over the past decade, the use of the monoclonal antibody alemtuzumab in chronic lymphocytic leukemia has expanded from administration as a single-agent therapy, into use in combination with fludarabine or rituximab, and further to use as a consolidation agent with the goal of eradica...
|
PMID: 21685865
PDF is available here.
PDF is available here.
Abstract
We describe a 56-year-old woman who presented with fatigue and easy bruising, eventually became pancytopenic, and was diagnosed with MDS. After treatment with a clinical protocol using alemtuzumab, an anti-CD52 antibody, her blood cell counts returned to normal and she has remained in complete remis...
|
PMID: 21343581
PDF is available here.
PDF is available here.
Abstract
We tested the feasibility of alemtuzumab dose deescalation in the context of fludarabine-melphalan conditioning and human leukocyte antigen (HLA)-identical sibling transplantation. Alemtuzumab was given 1-2 days before graft infusion, and dose reduced from 60 mg to 20 mg in 4 sequential cohorts (tot...
|
PMID: 20587785
PDF is available here.
PDF is available here.
Abstract
The treatment of acute lymphocytic leukemia (ALL) results in long-term disease-free survival in only 30-40% of adults. Conventional chemotherapy is toxic and woefully ineffective. Therefore, novel agents are being investigated. Among these agents are monoclonal antibodies such as rit...
|
PMID: 20680526
PDF is available here.
PDF is available here.
Journal of Proteomics (73)10 2010
Abstract
We provide an extensive review of the outcome of these studies in terms of protein identifications (protein numbers and regulated proteins), with an emphasis on the methods used and the limitations of the studies with regard to biomarker discovery. This is followed by a perspective on novel technolo...
|
PMID: 20332038
PDF is available here.
PDF is available here.
Clinical Immunology (136)3 2010
Abstract
We found the alterations of Paneth cells including abnormal Paneth cell granules and expression of lysozyme and defensin 5 in response to lymphocyte depletion by alemtuzumab. Lymphocyte depletion resulted in decreased expression of TNF-alpha, IFN-gamma, IL-10 and TGF-beta in the intestine. The diver...
|
PMID: 20605528
PDF is available here.
PDF is available here.
Abstract
We describe the generation of a novel IgG-based immunotoxin, designated 2L-Rap(Q)-hRS7, comprising Rap(Q), a mutant Rap with the putative N-glycosylation site removed, and hRS7, an internalizing, humanized antibody against Trop-2, a cell surface glycoprotein overexpressed in variety of epithelial ca...
|
PMID: 20663928
PDF is available here.
PDF is available here.
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences (35)8 2010
Abstract
To compare the in vitro antitumor immune responses induced by bivalent bispecific anti-idiotype antibody G22-I50 and monovalent anti-idiotype antibody G22 and I50, and explore its possible mechanism.
Proteins G22-I50, G22, and I50 were induced and identified by Wester...
|
PMID: 20818068
PDF is available here.
PDF is available here.
Experimental Hematology (38)8 2010
Abstract
Following CEACAM6 cross-linking in ALL cells, we detected Erk1/2, Akt, and p38 MAPK phosphorylation and integrin upregulation, as well as enhanced binding of integrin ligands (vascular cell adhesion molecule-1 [VCAM-1] and intercellular cell adhesion molecule-1 [ICAM-1]). However, CEACAM6 signaling...
|
PMID: 20380867
PDF is available here.
PDF is available here.
Abstract
A 39-year-old woman with no relevant medical or family history was admitted to hospital with episodic fever, which persisted despite antibiotic therapy. Other notable findings at admission were splenomegaly, pancytopenia, hyponatremia, elevated levels of liver enzymes, hyperferritine...
|
PMID: 20404855
PDF is available here.
PDF is available here.
Journal of Proteomics (73)8 2010
Abstract
Sample pre-treatment is a critical step for an efficient and reliable analysis and it is highly dependent on the complexity of the matrix. This work shows an example of application of an immunoprecipitation approach using a new magnetic beads-based format, which allows a selective/sp...
|
PMID: 20206311
PDF is available here.
PDF is available here.
Abstract
The purpose of this study was to assess two-step in vivo tumor targeting by specific biotin-conjugated antibodies and ultrasmall superparamagnetic iron oxide (USPIO)-anti-biotin nanoparticles as contrast agents for magnetic resonance imaging (MRI) at 1.5 T.
D430B huma...
|
PMID: 19806404
PDF is available here.
PDF is available here.
Abstract
We present evidence that cervical cancer cells express a functional IL-2 receptor (IL-2R). In fact, by RT-PCR we obtained that the IL-2R is present in CALO, and INBL cells, and that it consisted of the alphaIL-2R, betaIL-2R, and gammaIL-2R chains. We also found that IL-2 is a growth factor for these...
|
PMID: 20227890
PDF is available here.
PDF is available here.
Analyst (Cambridge UK) (135)5 2010
Abstract
Our study provided a novel approach to the pretreatment of biomedical data....
|
PMID: 20419233
PDF is available here.
PDF is available here.
Journal of Immunological Methods (355)1-2 2010
Abstract
A procedure is described for the disaggregation of colorectal cancers (CRC) and normal intestinal mucosal tissues to produce suspensions of viable single cells, which are then captured on customized antibody microarrays recognising 122 different surface antigens (DotScan CRC microarray). Cell bindin...
|
PMID: 20156443
PDF is available here.
PDF is available here.
Abstract
Current Gene Therapy (10)2 2010
Abstract
We provide a structural overview of CAR development and highlight areas that require further refinement. We also attempt to identify possible reasons for conflicting results in the hope that this information will inspire future rational design strategies for optimal tumour targeting using CARs....
|
PMID: 20222863
PDF is available here.
PDF is available here.
Abstract
We report a case of CMV ventriculoencephalitis after unrelated double cord blood SCT with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia....
|
PMID: 20358010
PDF is available here.
PDF is available here.
Abstract
We analyzed the impact of prophylactic CD8-depleted (CD8(depl)) DLI in 20 recipients of anti-CD52 alemtuzumab in vivo T-cell-depleted allografts with declining donor TCC after day +60. A total of 13 patients received CD8(depl) DLI and 7 patients did not. All but one of the DLI patients converted to...
|
PMID: 19684624
PDF is available here.
PDF is available here.
Abstract
We report a retrospective analysis of 128 consecutive patients with high-risk myelodysplastic syndrome (MDS) and AML who received an alemtuzumab-based reduced-intensity conditioning hematopoietic SCT (RIC HSCT). The median recipient age was 53 years (range 21-72 years). A total of 49 (38%) recipient...
|
PMID: 19767782
PDF is available here.
PDF is available here.
La Revue du praticien (60)3 2010
Abstract
Methods in Molecular Biology (624)624 2010
Abstract
We will also discuss FSNP surface modification and bioconjugation techniques that are useful for cancer cell imaging....
|
PMID: 20217594
PDF is available here.
PDF is available here.
Abstract
Dual targeting of 2 distinct molecules in tumors such as TAG-72 and HER-2 with alpha-particle radiation resulted in an enhanced, additive, therapeutic benefit. The authors also observed that this radioimmunotherapeutic strategy was well tolerated.
Published 2010 by the American Cancer Society....
|
PMID: 20127951
PDF is available here.
PDF is available here.
Abstract
We have previously shown in mice that vaccination with three Her-2-peptides representing B-cell epitopes of the extracellular domain of Her-2/neu induces Her-2/neu-specific IgG antibodies with strong anti-tumor activity in vitro and in vivo. We have now finalized a phase I clinical trial with an ant...
|
PMID: 20092022
PDF is available here.
PDF is available here.
Abstract
We reviewed the histopathology of the explanted lungs from 304 patients who underwent lung transplantation at our institution from 2005 to 2007 and received alemtuzumab induction therapy and posttransplant voriconazole prophylaxis.
Invasive mold infections were present in the explanted lungs of 5% (...
|
PMID: 20098291
PDF is available here.
PDF is available here.
Abstract
We performed proof-of-concept studies investigating the therapeutic potential and mechanism of action of monoclonal antibody (mAb)-based therapy against CD73, an ecto-enzyme overexpressed on breast-cancer cells that catalyzes the dephosphorylation of adenosine monophosphates into adenosine. We showe...
|
PMID: 20080644
PDF is available here.
PDF is available here.
Acta Cytologica (54)5 Suppl 2010
Abstract
Abstract
We demonstrate that GGS-NPs exposed to a pulsed, NIR laser exhibit two-photon induced photoluminescence that can be utilized to visualize cancerous cells in vitro. When conjugated with anti-HER2 antibodies, these nanoparticles specifically bind SK-BR-3 breast carcinoma cells that over-express the HE...
|
PMID: 20957166
PDF is available here.
PDF is available here.
Abstract
Antibody-targeted superantigen has been developed into a new strategy to treat many malignant tumors. In this study, for specific targeting to gastric cancer cell, superantigen SEB (Staphylococcal Enterotoxin B) was genetically fused to the single-chain variable fragment of gastric carcinoma-associa...
|
PMID: 20339532
PDF is available here.
PDF is available here.
BMC Biotechnology (10)1 2010
Abstract
We concluded that isolation and detection of CTC with immunomagnetic enrichment methods is critically dependent on the used EpCAM clone. Further studies with a larger number of patients should clarify if the enrichment protocol influences the prognostic value of the tumor cell detection protocol....
|
PMID: 20426872
PDF is available here.
PDF is available here.
Abstract
We found that orthotopic tumors responded much less to treatment (approximately 13% survival), but a significant improvement in survival was achieved through the addition of IL-2 to the treatment regimen (55% survival). All three agonist antibodies and high dose IL-2, 100,000 IU for up to six doses,...
|
PMID: 20426873
PDF is available here.
PDF is available here.
Abstract
The infection rate is considerably high with both protocols. Alemtuzumab seems to offer better immunosuppression against ACRs during the first month posttransplantation....
|
PMID: 20172276
PDF is available here.
PDF is available here.
Abstract
Our preliminary experience in these 5 cases showed that the protocol combining alemtuzumab induction therapy with low-dose tacrolimus monotherapy without maintenance steroid therapy past-SBTx can effectively control rejection with excellent graft function. Nevertheless, close surveillance of ACR sho...
|
PMID: 20172275
PDF is available here.
PDF is available here.
Abstract
A good and early reconstitution of CMV-specific T-cell immune responses after transplantation is a critical determinant in controlling CMV infections. Simultaneous monitoring of CMV infection and CMV-specific T-cell immunity predicts T-cell-mediated control of CMV infection....
|
PMID: 20172283
PDF is available here.
PDF is available here.
Evaluation of late immunologic parameters among renal transplant recipients induced with Campath-1H.
Abstract
We compared Treg at 4 and 20 months posttransplant, observing a decline from a mean of 19.9% to 5.9% (P = .05). In seven recipients, posttransplant PRA was determined; five of them became "de novo" sensitized, three with a mean class I PRA of 16% and two with a mean class II PRA of 37%. In conclusio...
|
PMID: 20172322
PDF is available here.
PDF is available here.
Abstract
This meeting report on the fourth Fabisch Symposium for Cancer Research and Molecular Biology describes the aims of the international meeting, the main topics of the presentations, and the highlights of the conference. The fourth Fabisch Symposium was the second on Targeted Tumor The...
|
PMID: 20053770
PDF is available here.
PDF is available here.
Abstract
This meeting report on the fourth Fabisch Symposium for Cancer Research and Molecular Biology describes the aims of the international meeting, the main topics of the presentations, and the highlights of the conference. The fourth Fabisch Symposium was the second on Targeted Tumor The...
|
PMID: 20053770
PDF is available here.
PDF is available here.
Abstract
This meeting report on the fourth Fabisch Symposium for Cancer Research and Molecular Biology describes the aims of the international meeting, the main topics of the presentations, and the highlights of the conference. The fourth Fabisch Symposium was the second on Targeted Tumor The...
|
PMID: 20053770
PDF is available here.
PDF is available here.
Abstract
We observed that at the lowest treatment dose (2.5 microg/kg: twice daily for 4 days) A-dmDT(390)-bisFv(UCHT1) depletes greater than 99.0% of normal T cells in all six patients for a short period of time (2-3 days) and that there is no association of C (max) and extent of T-cell depletion with the p...
|
PMID: 20686966
PDF is available here.
PDF is available here.
Abstract
The aim of this study to determine whether serum p53 protein and antibodies are associated with malignant tumors. A case-control study was conduct in 569 patients with various types of malignant tumors and 879 healthy controls. Serum p53 protein and antibodies were analyzed by enzyme-linked immunoso...
|
PMID: 19693693
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
The large experience accumulated with the therapeutic use of monoclonal antibodies has revealed undesirable effects, among which opportunistic infections when prescribed in inflammatory or hematological diseases. This deleterious effect is a direct consequence of the immunosuppression induced by the...
|
PMID: 20035693
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
Rituximab, a chimeric monoclonal anti-CD20 antibody, was introduced into clinical practice in 1997, and has proven to be highly effective in the treatment of B-lymphoproliferative disorders and autoimmune diseases. Despite such success, in vivo mechanisms of action of anti-CD20 have only recently be...
|
PMID: 20035683
PDF is available here.
PDF is available here.
Leukemia & Lymphoma (50)12 2009
Abstract
We present the results of an open-label clinical trial and the clinical use of alemtuzumab in 19 heavily pretreated patients with advanced erythrodermic cutaneous T-cell lymphomas (CTCL) (erythrodermic mycosis fungoides and Sézary syndrome). Ten patients received alemtuzumab intravenously using an...
|
PMID: 19860617
PDF is available here.
PDF is available here.
Abstract
Abstract
The ELISA results indicated that patients with high antibody response to HPV16E7 had significant seroreactivity to CT-gp96 fragment. In Western blot analysis, a strong association between anti-E7, anti-NT-gp96 and anti-CT-gp96 reactivity and cervical cancer was obtained using purified recombinant pr...
|
PMID: 20090101
PDF is available here.
PDF is available here.
Methods in Molecular Biology (576)576 2009
Abstract
During the development of tumors, autoantibodies against aberrant or overexpressed autoantigens can be induced. Several hundreds of tumor-associated autoantibodies (TAAB) with more or less specificity for tumors have been found until now by molecular cloning and proteomics technologies. Many TAAB ar...
|
PMID: 19882265
PDF is available here.
PDF is available here.
Leukemia & Lymphoma (50)11 2009
Abstract
We analyzed the kinetics of CD3 chimerism in 120 consecutive allogeneic hematopoietic cell transplantation (HCT) recipients receiving alemtuzumab-based conditioning. Fifty-two received fludarabine/melphalan, 44 received fludarabine/busulfan, and 24 received clofarabine/melphalan in addition to alemt...
|
PMID: 19821799
PDF is available here.
PDF is available here.
Rinsho Shinkeigaku (49)11 2009
Abstract
Zhonghua Yixue Zazhi (89)38 2009
Abstract
The partial tolerance steroid-free protocol of combining Campath 1H induction with a low-dose monotherapy of tacrolimus can effectively control the graft rejection in small bowel transplantation. And the grafted intestine regains an excellent function....
|
PMID: 20137270
PDF is available here.
PDF is available here.
Abstract
We review the pathophysiology associated with an increased risk for aspergillosis in these patients, in addition to diagnostic and therapeutic considerations....
|
PMID: 19635439
PDF is available here.
PDF is available here.
Transplantation (88)7 2009
Abstract
One thousand nine hundred thirteen recipients received alemtuzumab and 7011 received IL-2RA. There were few significant differences in baseline characteristics. The incidence of acute rejection at discharge was lower in the alemtuzumab group, when compared with that in the IL-2RA group (0.8% vs. 4.4...
|
PMID: 19935462
PDF is available here.
PDF is available here.
Leukemia & Lymphoma (50)10 2009
Abstract
We examined the impact of alemtuzumab treatment after initial fludarabine treatment for feasibility and safety. Patients (N = 85) with previously untreated symptomatic CLL received fludarabine (25 mg/m(2)/day) for 5 days every 4 weeks for four cycles followed by 2 months of observation. Patients wit...
|
PMID: 19863336
PDF is available here.
PDF is available here.
Leukemia & Lymphoma (50)10 2009
Abstract
Transplantation (88)6 2009
Abstract
We conducted a prospective randomized single-center trial comparing alemtuzumab and rATG induction in adult kidney and pancreas transplantation in patients treated with similar maintenance immunosuppression. RESULTS.: Between February 1, 2005, and September 1, 2007, 222 patients randomly received ei...
|
PMID: 19920781
PDF is available here.
PDF is available here.
Transplantation (88)6 2009
Abstract
We sought to evaluate the role of alemtuzumab induction in this population.
We evaluated 144 patients undergoing kidney transplantation after nonrenal transplantation between May 18, 1998, and October 8, 2007. Seventy-two patients transplanted between January 15, 2003, and October 8, 2007, received...
|
PMID: 19920779
PDF is available here.
PDF is available here.